ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

77.50 -0.35 (-0.45%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	446,235
Open	78.36
Bid (Size)	77.60 (200)
Ask (Size)	78.50 (100)
Prev. Close	77.85
Today's Range	76.51 - 78.95
52wk Range	0.4681 - 78.95
Shares Outstanding	183,801,441
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm

April 09, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

April 09, 2026

From Schall Law

Via GlobeNewswire

Performance

YTD	+78.5%	+78.5%
1 Month	+5.7%	+5.7%
3 Month	+95.2%	+95.2%
6 Month	+42.6%	+42.6%
1 Year	+15428.0%	+15428.0%

More News

NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline

April 09, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR

April 07, 2026

From Pomerantz LLP

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)

April 07, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

April 06, 2026

From Schall Law

Via GlobeNewswire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

April 03, 2026

From Schall Law

Via GlobeNewswire

NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline

April 02, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

April 02, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky

March 31, 2026

From Levi & Korsinsky, LLP

Via Business Wire

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR

March 31, 2026

From Pomerantz LLP

Via GlobeNewswire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

March 31, 2026

From Schall Law

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)

March 31, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

NEKTAR CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm

March 27, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline

March 26, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

March 25, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

March 25, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky

March 24, 2026

From Levi & Korsinsky, LLP

Via Business Wire

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR

March 24, 2026

From Pomerantz LLP

Via GlobeNewswire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

March 24, 2026

From Schall Law

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)

March 24, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

March 23, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

March 20, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

2 Healthcare Stocks to Buy Before They Get Bought Out ↗

March 20, 2026

Via The Motley Fool

ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

March 19, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Frequently Asked Questions

Is Nektar Therapeutics - Common Stock publicly traded?

Yes, Nektar Therapeutics - Common Stock is publicly traded.

What exchange does Nektar Therapeutics - Common Stock trade on?

Nektar Therapeutics - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Nektar Therapeutics - Common Stock?

The ticker symbol for Nektar Therapeutics - Common Stock is NKTR on the Nasdaq Stock Market

What is the current price of Nektar Therapeutics - Common Stock?

The current price of Nektar Therapeutics - Common Stock is 77.50

When was Nektar Therapeutics - Common Stock last traded?

The last trade of Nektar Therapeutics - Common Stock was at 04/10/26 04:00 PM ET

What is the market capitalization of Nektar Therapeutics - Common Stock?

The market capitalization of Nektar Therapeutics - Common Stock is 14.24B

How many shares of Nektar Therapeutics - Common Stock are outstanding?

Nektar Therapeutics - Common Stock has 14B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.